TOP HEADLINES

Featured Story

Merck KGaA deal for Sigma-Aldrich gets it some specialty manufacturing capacity

Merck KGaA may have struggled getting new drug products to market, but its $17 billion buyout of Sigma-Aldrich will allow it to help others, as well as itself, in that endeavor.

Natco India plant gets Form 483 from FDA

Indian drug maker Natco has joined a long list of compatriots facing FDA concerns over manufacturing issues. According to The Financial Express, the company received an FDA Form 483 for a finished dosage plant in Telangana after an inspection in May.

Novartis says more cuts coming for New York Diovan plant

Novartis has notified the state of New York of its 83-employee layoff beginning Dec. 31 at its plant in Suffern, NY, a facility that will close in 2016, at which point essentially all traces of it will be eliminated.

Baxter issues recall, this time because antibacterial gets mixed in wrong carton

Baxter International is again recalling a sodium chloride product, but this time, instead of particulate contamination, it is because another product was mistakenly mixed in the shipment.

FDA procedural delay on Rytary gives Impax breathing room

The FDA has put off reconsideration of Impax Laboratories' Parkinson drug Rytary. The delay will give the California company some additional time to work on the latest in a series of FDA concerns over its manufacturing that have kept the drug sidelined.

MORE NEWS